Updates are available Correction dated 2020-06-12
Click to view Correction: https://doi.org/10.1186/s40035-020-00207-0
-
Authors
Swindell, William R. http://orcid.org/0000-0001-8504-6363
Bojanowski, Krzysztof
Kindy, Mark S.
Chau, Raymond M. W.
Ko, Dorothy
-
Funding
Funding for this research was provided by:
Genervon Biopharmaceuticals
- License Information
-
More Information
Article History
Received: 2 July 2018
Accepted: 21 October 2018
First Online: 3 December 2018
Change Date: 12 June 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: GM604 is an investigational drug product developed by Genervon Biopharmaceuticals, LLC (Pasadena, CA). DK is an executive of Genervon with ownership interest and has been listed as an inventor for patents related to GM604. RMWC is a Genervon associate, has been listed as an inventor for patents related to GM604, and has received consulting reimbursement from Genervon Biopharmaceuticals. MK has been listed as an inventor on patents related to GM604 and has received consulting reimbursement from Genervon Biopharmaceuticals. KB is chief executive officer of Sunny BioDiscovery, Inc. (Santa Paula, CA) and has received consulting reimbursement from Genervon Biopharmaceuticals. WRS has been listed as an inventor for pending patent applications related to GM604 and has received consulting reimbursement from Genervon Biopharmaceuticals.
